New Nasal Applicator / New Formulation - User Study
The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua
(new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the
symptoms of seasonal allergic rhinitis (SAR).
Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome
University of Louisville
-Intranasal budesonide therapy may lead to improved symptoms and sleep study findings in
children with mild obstructive sleep apnea with and without allergic rhinitis that would not
be treated with T&A. The aim of the study is to conduct a randomized double blind cross-over
trial comparing the effect of once a day intranasal budesonide therapy vs. placebo in
children with mild sleep apnea that would not be candidates for T&A.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.